Assay for the prediction of therapeutic effectiveness of mesenchymal stromal cells, and methods of using same
AssigneeAllocure, Inc.
InventorChristof Westenfelder
Life of this patent
Estimating the term…
Abstract
The invention relates to assays for testing the therapeutic effectiveness of mesenchymal stromal cell (MSC) populations and methods of treating pathologies with passaged and/or frozen and thawed MSC populations.
Claims54
A method of assaying the therapeutic effectiveness of mesenchymal stromal cells (MSCs) for treating a pathology in a subject comprising:
- (a) isolating a first population of MSCs, wherein the first population of MSCs has been freshly isolated;
- (b) isolating a second population of MSCs, wherein the second population has been passaged and/or frozen and thawed;
- (c) measuring the expression of stromal derived factor-1 (SDF-1) and/or vascular endothelial growth factor (VEGF) in the first and second populations;
- and
- (d) comparing the expression of SDF-1 and/or VEGF in the first and second populations;
- wherein, if the expression of SDF-1 and/or VEGF in the second population is the same as or greater than the expression of SDF-1 and/or VEGF in the first population the second population contains MSCs that are therapeutically effective.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating an MSC related pathology in a subject in need thereof comprising:
- (a) isolating a first population of MSCs, wherein the first population of MSCs has been freshly isolated;
- (b) isolating a second population of MSCs, wherein the second population has been passaged one or more times and/or frozen and thawed;
- (c) measuring the expression and/or secretion into the media of stromal derived factor-1 (SDF-1) and/or vascular endothelial growth factor (VEGF) in the first and second populations;
- and
- (d) comparing the expression of SDF-1 and/or VEGF in the first and second populations;
- wherein, if the expression of SDF-1 and/or VEGF in the second population is the same as or greater than the expression of SDF-1 and/or VEGF in the first population the second population contains MSCs that are therapeutically effective;
- and a therapeutically effective dose of the MSCs in the second population is administered to the subject, thereby treating the MSC related pathology in the subject.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of producing a dosage form of MSCs comprising:
- (a) isolating a first population of MSCs, wherein the first population of MSCs has been freshly isolated;
- (b) isolating a second population of MSCs, wherein the second population has been passaged one or more times and/or frozen and thawed;
- (c) measuring the expression of stromal derived factor-1 (SDF-1) and/or vascular endothelial growth factor (VEGF) in the first and second populations;
- and
- (d) comparing the expression of SDF-1 and/or VEGF in the first and second populations;
- wherein, if the expression of SDF-1 and/or VEGF in the second population is the same as or greater than the expression of SDF-1 and/or VEGF in the first population the second population of MSCs are combined with a physiologically acceptable solution, thereby producing a dosage form of MSCs.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.